Condition: Prostate Cancer · Sponsor: Institute of Cancer Research, United Kingdom
The i4i PRODICT® study has been developed to investigate the uptake and acceptability of the i4i PRODICT® test which combines both common and rare genetic changes (genetic variants) into one saliva-based DNA test to estimate a person's future risk of prostate cancer (PrCa) in people of varying ethnicities.
This description comes directly from the study's public registry record.
Eva McGrowder, PhD · +44 208 722 4483 · Eva.McGrowder@icr.ac.uk
Elizabeth K Bancroft, PhD · +44 208 722 4483 · elizabeth.bancroft@rmh.nhs.uk
Always discuss trial participation with your own doctor first.
| The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust | Sutton, Surrey, United Kingdom | Recruiting |
| The Royal Marsden Hospital | London, United Kingdom | Recruiting |
| The Royal Marsden Hospital | Sutton, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06636526